Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 5, Pages 446-460
Publisher
Wiley
Online
2015-04-23
DOI
10.1002/ajh.23979
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
- (2015) M. Borge et al. HAEMATOLOGICA
- Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
- (2015) M. Borge et al. HAEMATOLOGICA
- Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
- (2014) G. Cartron et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
- (2014) N. Pflug et al. BLOOD
- Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
- (2014) P. Dreger et al. BLOOD
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
- (2013) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
- (2013) M. Hallek BLOOD
- The Role of Minimal Residual Disease Measurements in the Therapy for CLL
- (2013) Sebastian Böttcher et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
- (2013) D Cortese et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- FCA: Forget Chemoimmunotherapy with Alemtuzumab?
- (2012) M. Hallek BLOOD
- Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor
- (2012) N. Reinart et al. BLOOD
- Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial
- (2012) S. Lepretre et al. BLOOD
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2012) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel CD20 monoclonal antibodies for lymphoma therapy
- (2012) Shundong Cang et al. Journal of Hematology & Oncology
- Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
- (2012) V Goede et al. LEUKEMIA
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells
- (2012) Mirjam Kuckertz et al. Oncology Research and Treatment
- Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
- (2011) S. A. Parikh et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals
- (2011) Alison M. MCCaig et al. BRITISH JOURNAL OF HAEMATOLOGY
- Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia
- (2011) Yoshikane Kikushige et al. CANCER CELL
- Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
- (2011) J. M. Tromp et al. CLINICAL CANCER RESEARCH
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2011) P. C. Amrein et al. CLINICAL CANCER RESEARCH
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
- (2011) Craig Reynolds et al. INVESTIGATIONAL NEW DRUGS
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
- (2011) Thomas Elter et al. LANCET ONCOLOGY
- Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia
- (2011) Martina Seiffert et al. LEUKEMIA & LYMPHOMA
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia
- (2010) Junia V. Melo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
- (2010) Michaela Patz et al. BRITISH JOURNAL OF HAEMATOLOGY
- The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
- (2010) Ulf Klein et al. CANCER CELL
- Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
- (2010) M W Harr et al. CELL DEATH AND DIFFERENTIATION
- Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia
- (2010) Fredrick Hagemeister DRUGS
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
- (2010) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
- (2010) J R Brown et al. LEUKEMIA
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
- (2010) Taimur Sher et al. LEUKEMIA & LYMPHOMA
- Prognostic factors in chronic lymphocytic leukemia—what do we need to know?
- (2010) Paula Cramer et al. Nature Reviews Clinical Oncology
- The microenvironment in mature B-cell malignancies: a target for new treatment strategies
- (2009) J. A. Burger et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
- (2009) Francesc Bosch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2009) Wolfgang U. Knauf et al. JOURNAL OF CLINICAL ONCOLOGY
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- State-of-the-art treatment of chronic lymphocytic leukemia
- (2009) M. Hallek Hematology-American Society of Hematology Education Program
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes
- (2008) A. Veldurthy et al. BLOOD
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
- (2008) K. Balakrishnan et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro
- (2008) Lilian Amrein et al. BRITISH JOURNAL OF HAEMATOLOGY
- Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
- (2008) Carmen D. Schweighofer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Validation of a new prognostic index for patients with chronic lymphocytic leukemia
- (2008) Tait D. Shanafelt et al. CANCER
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Disease burden of chronic lymphocytic leukaemia within the European Union
- (2008) Louise Watson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2008) Kenneth A. Foon et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
- (2008) S Gobessi et al. LEUKEMIA
- Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
- (2008) Andy C. Rawstron et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started